SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Clinical trials for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF HEAD AND NECK trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to boost head and neck cancer treatment
Disease control OngoingThis study tests whether giving two drugs, pembrolizumab and olaparib, before and after standard chemoradiation can help people with advanced head and neck cancer. About 45 adults will take part. The goal is to see if this approach delays cancer growth or improves survival.
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:31 UTC
-
Shorter radiation after head and neck cancer surgery may ease swallowing troubles
Disease control OngoingThis study tests a shorter course of radiation therapy given after surgery for head and neck cancer. The goal is to see if it is safe, tolerable, and helps preserve swallowing function compared to standard longer radiation. About 59 adults with certain types of head and neck canc…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1, PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated May 26, 2026 03:29 UTC
-
Custom-Made vaccine aims to keep head and neck cancer from coming back
Disease control OngoingThis study tests a personalized immunotherapy called TG4050 in 80 people with newly diagnosed, advanced head and neck cancer. Participants receive the treatment after standard therapy to see if it safely delays the cancer's return. The approach targets unique mutations in each pa…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1, PHASE2 • Sponsor: Transgene • Aim: Disease control
Last updated May 26, 2026 03:29 UTC
-
Nanoparticles + radiation + immunotherapy: a new triple attack against advanced cancers enters human testing
Disease control OngoingThis early-phase study tests a new treatment for people with advanced cancers that have not responded well to standard care. The treatment combines NBTXR3 (tiny particles injected into the tumor), radiotherapy, and an immunotherapy drug (anti-PD-1). The goal is to see if this tri…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1 • Sponsor: Nanobiotix • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, melanoma, and kidney cancer. The main goal is to find a safe dose and understand side effects. About 126 participants will take part to see if the treatm…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
Custom-Made vaccine targets tough cancers in early trial
Disease control TerminatedThis early-phase trial tests a personalized vaccine (PANDA-VAC) made from a patient's own tumor mutations, given alongside the immunotherapy drug pembrolizumab. The study includes up to 6 adults with advanced squamous lung or head/neck cancer that cannot be cured. The main goal i…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
New drug combo shows promise in early cancer trial
Disease control OngoingThis early-phase study tests a new drug called AB248, alone or with another drug (pembrolizumab), in adults with advanced solid tumors (like lung, skin, head/neck, or kidney cancer) that have not been cured by other treatments. The main goal is to check the drug's safety and find…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1 • Sponsor: Asher Biotherapeutics, Inc. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Cancer drug trial pulled before it even started
Disease control TerminatedThis trial aimed to see if the drug TTI-101 could shrink HPV-negative head and neck cancers when given just before planned surgery. It was designed for people with stage II to IV cancer that could be removed. However, the study was withdrawn before enrolling any participants, so …
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Immune cells take on head and neck cancer in early trial
Disease control OngoingThis early-phase study tests a new treatment called TBio-4101, which uses a patient's own immune cells (TILs) to fight advanced head and neck cancer. Participants receive these cells along with pembrolizumab, with or without chemotherapy. The main goal is to check safety in a sma…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
New microscope could spot cancer cells Mid-Surgery
Diagnosis OngoingThis study tests a special microscope that helps surgeons see if any cancer cells are left behind during skin cancer removal. About 42 adults with head, neck, or skin cancer will take part. The goal is to see if this microscope works as well as standard lab tests to guide surgery…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: NA • Sponsor: Institut de Cancérologie de Lorraine • Aim: Diagnosis
Last updated May 26, 2026 03:30 UTC
-
Spit and blood may reveal hidden signs of head and neck cancer
Knowledge-focused OngoingThis study collects saliva, blood, and tissue samples from 225 adults with or without head and neck cancer to find tiny genetic markers called miRNAs. Researchers want to see if these markers can help predict how the disease will progress or aid in diagnosis. Participants include…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated May 26, 2026 03:03 UTC
-
New drug combo studied in head and neck cancer before surgery
Knowledge-focused OngoingThis study looks at how a protein called AXL in head and neck tumors responds to a combination of two drugs, imatinib and cetuximab, given before standard treatment like surgery or radiation. About 15 adults with head and neck cancer will receive the drugs for a short time, then …
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: EARLY_PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC